All Updates

All Updates

icon
Filter
Funding
Nimbus Therapeutics raises USD 210 million in private financing round
AI Drug Discovery
Sep 6, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Sep 6, 2023

Nimbus Therapeutics raises USD 210 million in private financing round

Funding

  • Massachusetts-based AI biotechnology company Nimbus Therapeutics has raised USD 210 million in a private funding round co-led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture. The round also saw participation from existing investors Bain Capital Life Sciences and Pfizer Ventures.

  • The funds raised will be used to advance Nimbus Therapeutics' pipeline of drugs for various disorders, including ongoing trials of its hematopoietic progenitor kinase 1 inhibitor in solid tumors. Further, the company aims to use these proceeds to target Werner syndrome helicase and an undisclosed immune target, as well as develop novel therapies for metabolic disorders through a partnership with Eli Lilly.

  • The fund raise follows the company’s USD 6 billion sales of its fully-owned subsidiary, Nimbus Lakshmi, and its Tyrosine kinase 2 (TYK2) (intracellular enzyme) program to Takeda Pharmaceuticals in February 2023 .

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.